From an Enterprise to an Era
May 19 – 20, 2022 • Ritz-Carlton Laguna Niguel, Dana Point, CA
Schedule
PART I
Assessing an Evolving Scientific, Business, and Policy Landscape
SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition
Following the approval of Kite’s first chimeric antigen receptor (CAR) T-cell therapy in 2017, the company set its sights on delivering these highly personalized treatments to every patient who can benefit. Then COVID-19 upended the landscape for delivering cancer care. During this wide-ranging keynote fireside chat, Kite CEO Christi Shaw will reflect on the company’s journey thus far and share her perspectives on the future of personalized medicine and cancer care.
MODERATOR | Clifton Leaf, Global Fellow, Ellison Institute for Transformative Medicine
KEYNOTE SPEAKER | Christi Shaw, CEO, Kite, a Gilead Company
LEARN MOREThe devastating effects of COVID-19 exposed the shortcomings of the modern biomedical enterprise. But the pandemic also demonstrated medicine’s ability to move further, faster. During this panel discussion, a cross-sector group of thought leaders will convene to consider what the lessons learned from the pandemic may mean for the future of personalized medicine.
MODERATOR | Jay G. Wohlgemuth, M.D., Chief Medical Officer, Senior Vice President, Research and Development, Medical, Population Health, Quest Diagnostics
Alex J. Carlisle, Ph.D., Founder, Chairman, CEO, National Alliance Against Disparities in Patient Health
Kris Joshi, Ph.D., Executive Vice President, President, Network Solutions, Change Healthcare
Lauren Silvis, Senior Vice President of External Affairs, Tempus
LEARN MORESponsored by
Molecular diagnostics, more sophisticated approaches to analyzing health care data, and molecularly guided treatments for non-oncologic indications are expanding the frontiers of personalized medicine outside of oncology. But progress remains uneven across disease states. During this panel discussion, leaders in the field will join us to explore the opportunities and challenges for personalized medicine in multiple disease states.
MODERATOR | Elizabeth O’Day, Ph.D., CEO, Founder, Olaris
William Hagstrom, Founder, CEO, Octave Bioscience
Dan M. Roden, M.D., Senior Vice President for Personalized Medicine, Vanderbilt University Medical Center
Catherine Sanders, Ph.D., Vice President, Research and Business Development, Adaptive Biotechnologies
LEARN MOREIn the era of personalized medicine, health care researchers are aligning their work more closely with patients’ values, circumstances, and preferences. After two years of discussions convened by the Personalized Medicine Coalition, patients will join us during this presentation and panel discussion to share principles and recommendations for conducting patient-centered personalized medicine research.
MODERATOR | Lori Frank, Ph.D., Senior Vice President, Research, Policy, and Programs, The New York Academy of Medicine; Medical, Scientific, and Memory Screening Advisory Board Member, Alzheimer’s Foundation of America
J. Michael Graglia, Co-Founder, Managing Director, SynGAP Research Fund
Laura Holmes Haddad, Writer/Patient Advocate
Richard Knight, President, American Association of Kidney Patients
LEARN MOREThe Annual Award for Leadership in Personalized Medicine recognizes an individual whose contributions in science, business, and policy have helped advance the frontiers of the field. This year’s award goes to Carl June, M.D., Richard W. Vague Professor in Immunotherapy, University of Pennsylvania. By paving the way for cancer treatments that use a patient’s own immune cells to combat cancer, Dr. June’s scientific discoveries have saved the lives of hundreds of patients and brought new hope to thousands.
PRESENTER | Stephen L. Eck, M.D., Ph.D., Senior Vice President, Clinical Development, Chief Medical Officer, MacroGenics
AWARDEE | Carl June, M.D., Richard W. Vague Professor in Immunotherapy, University of Pennsylvania
LEARN MOREAs the CEO of a diagnostics company focused on enabling “earlier, smarter answers across the cancer journey,” Kevin Conroy has broad-based ambitions for personalized medicine to transform cancer care. But realizing the promise of personalized medicine has been fraught with challenges since the human genome was first mapped in 2003. During this keynote address, Conroy will outline his vision for the future of the field.
INTRODUCTION | Michael J. Pellini, M.D., Managing Partner, Section 32
KEYNOTE SPEAKER | Kevin Conroy, CEO, President, Chairman of the Board, Exact Sciences
LEARN MOREThe diagnostics underpinning personalized medicine promise to improve health care by facilitating interventions at earlier stages of disease and targeting treatments to those who will benefit. The road to clinical adoption, however, is fraught with challenges. During this panel discussion, industry representatives will convene to discuss the outlook for transformative diagnostic tools designed to upend one-size-fits-all medicine.
MODERATOR | Tom Miller, Founder, Managing Partner, GreyBird Ventures
Okan Ekinci, M.D., Senior Vice President, Global Head of Marketing and Innovation, Roche Diagnostics Information Solutions
Megan P. Hall, Ph.D., Vice President, Medical Affairs, GRAIL
Peter Maag, Ph.D., Board Member, CareDx
Robert L. Nussbaum, M.D., Chief Medical Officer, Invitae
LEARN MORESponsored by
By providing information about how certain genes may affect a patient’s response to a drug, pharmacogenetic testing can inform personalized treatment strategies. But differing perspectives regarding the strength of the evidence supporting certain gene-drug interactions have slowed the pace at which clinicians are utilizing pharmacogenetic testing in clinical settings. During this panel discussion, a cross-sector group of thought leaders will convene to discuss the future of pharmacogenetic testing and personalized medicine.
MODERATOR | Howard McLeod, Pharm.D., Executive Clinical Director, Precision Health, Intermountain Healthcare
Kelly Caudle, Ph.D., Pharm.D., Principal Investigator and Director, Clinical Pharmacogenetics Implementation Consortium, St. Jude Children’s Research Hospital
Jami Elliott, Director, Global Business Development, Thermo Fisher Scientific
Don Rule, CEO, Founder, Translational Software
Jeffrey A. Shaman, Ph.D., Chief Science Officer, Coriell Life Sciences
LEARN MOREPayers have historically directed their resources toward medical interventions that will deliver immediate value to patients. But increased spending on personalized medicine may improve clinical and economic results over time. In this context, some payers have found innovative ways to cover groundbreaking personalized prevention and treatment strategies with extraordinary but understudied potential benefits. During this panel discussion, three payer representatives will share their perspectives on the evolving landscape for coverage and payment in personalized medicine.
MODERATOR | Michael J. Pellini, M.D., Managing Partner, Section 32
Jill Hagenkord, M.D., Chief Medical Officer, Optum Genomics
Thomas C. Hawes, M.D., Partner, Sandbox Industries; Member, BlueCross BlueShield Fund Management Team
Michael Sherman, M.D., Executive Vice President, Chief Medical Officer, Point32Health
LEARN MOREIn December of 2016, The Wall Street Journal lamented cancer-associated genetic mutations in the KRAS gene as “undruggable” targets. Less than five years later, Amgen won approval from the U.S. Food and Drug Administration for LUMAKRAS (sotorasib), a targeted therapy for certain lung cancer patients whose tumors express KRASG12C mutations. The historic approval underlines how personalized medicine is redefining the boundaries of medicine. But the road to commercialization presents many obstacles. During this closing keynote address, Amgen Senior Vice President for Research and Development Jean-Charles Soria will envision the future of personalized medicine and the pharmaceutical industry with attention to the scientific, business, and policy challenges associated with developing and commercializing targeted therapeutics.
INTRODUCTION | Randy Burkholder, Vice President, Policy and Research, PhRMA
KEYNOTE SPEAKER | Jean-Charles Soria, M.D., Ph.D., Senior Vice President, Research and Development, Amgen
LEARN MORESponsored by
PART II
Executing in a New Era
SPEAKER | Jay G. Wohlgemuth, M.D., Chief Medical Officer, Senior Vice President, Research and Development, Medical, Population Health, Quest Diagnostics
In 2007, when Janet Woodcock began a 13-year stint as the Director of the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research, there were less than five personalized medicines on the market. Today, there are more than 300. During this wide-ranging keynote address, the winner of the First Annual Award for Leadership in Personalized Medicine will join us to reflect on the progress and future of the field as she continues a tenure of public service spanning three decades and counting.
INTRODUCTION | Cynthia A. Bens, Senior Vice President, Public Policy, Personalized Medicine Coalition
KEYNOTE SPEAKER | Janet Woodcock, M.D., Principal Deputy Commissioner, U.S. Food and Drug Administration
LEARN MOREBy developing a unique library of compounds to target the kinase tree, Blueprint Medicines has been able to identify and develop new molecules and get them approved almost twice as fast as is typical. The result has been a robust pipeline and commercialization opportunities. Balancing all of these efforts was already challenging. The emergence of COVID-19 made it more so. Led by Harvard Business School’s Richard Hamermesh, this interactive case study discussion will consider the potential impact of Blueprint’s approach on the future of drug discovery and personalized medicine as well as the challenges that the pandemic posed.
LEADER | Richard Hamermesh, D.B.A., Co-Faculty Chair, Harvard Business School Kraft Precision Medicine Accelerator
GUEST SPEAKER | Kate Haviland, President, CEO, Blueprint Medicines
LEARN MORESponsored by
Recent research has revealed a “practice gap” in personalized cancer care whereby patients whose tumors test positive for key biomarkers never receive the corresponding targeted treatments that could have helped them. During this presentation, a Diaceutics executive will present the findings from a Personalized Medicine Coalition study that explores the factors contributing to this practice gap.
MODERATOR | Daryl Pritchard, Ph.D., Senior Vice President, Science Policy, Personalized Medicine Coalition
SPEAKER | Susanne Munksted, Chief Precision Officer, Diaceutics
LEARN MOREIn demonstrating that the vast majority of health care institutions are taking steps to integrate personalized medicine into clinical care, research findings published in the Journal of Personalized Medicine in March of 2021 underline the field’s evolution from a promising concept to a practical reality. But the Personalized Medicine Coalition study also spotlighted considerable opportunities to further optimize personalized medicine integration. This panel discussion will feature reflections on delivering personalized medicine from representatives of a clinical integration partner institution, an academic medical center that manages research and clinical care programs, an integrated health care delivery system that combines reimbursement and care delivery functions, and a community health care system that focuses predominantly on the delivery of care.
MODERATOR | Daryl Pritchard, Ph.D., Senior Vice President, Science Policy, Personalized Medicine Coalition
Lisa Alderson, Co-Founder, CEO, Genome Medical
Burns C. Blaxall, Ph.D., Director, Precision Medicine, The Christ Hospital Health Network
Lincoln Nadauld, M.D., Ph.D., Vice President, Chief of Precision Health and Academics, Intermountain Healthcare
Apostolia M. Tsimberidou, M.D., Ph.D., Professor, The University of Texas MD Anderson Cancer Center
LEARN MOREArtificial intelligence presents unprecedented opportunities to develop better predictive models for individual patients facing difficult decisions about the future of their care. But progress depends on pairing computational capacity with the right datasets. During this fireside chat, leaders from GNS Healthcare and the Multiple Myeloma Research Foundation (MMRF) will discuss the significance of their cross-sector collaboration to develop patient-specific models of disease progression and drug response using the data from MMRF’s CoMMpass Study.
MODERATOR | Mark P. Stevenson, Board Member, Personalized Medicine Coalition
Michael Andreini, President, CEO, Multiple Myeloma Research Foundation
Colin Hill, Chairman, CEO, Co-Founder, GNS Healthcare
LEARN MOREAs a pioneering leader in personalized medicine with a broad-based platform for advancing Alphabet Inc.’s ambitions in health care, Amy Abernethy sees tremendous opportunities on the horizon for patients and personalized medicine. During this closing keynote address, the former Principal Deputy Commissioner of the U.S. Food and Drug Administration will outline her data-driven vision for the future of the field.
INTRODUCTION | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition
KEYNOTE SPEAKER | Amy P. Abernethy, M.D., Ph.D., President, Clinical Studies Platforms, Verily
LEARN MORESPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition